Compare FedEx Corporation (FDX) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Nuvalent Inc — how do they compare? FedEx Corporation trades at $317.1 (market cap $74.78B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: FedEx Corporation is far larger — about 7.6× Nuvalent Inc's market cap, and FedEx Corporation pays a 1.56% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| FDX | NUVL | |
|---|---|---|
Market Cap | $74.78B | $9.81B |
Sector | Industrials | Technology |
52-Week High | $338.75 | $123.96 |
52-Week Low | $174.81 | $72.16 |
Enterprise Value | $104.42B | $8.52B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $316.24, up 0.82% on the day, with a bearish technical signal despite recent earnings beats. The company shows steady revenue near $88B and net income of $4.09B in 2025, supported by a P/E of 16.9 and strong analyst consensus. Recent developments include the sale of FedEx Supply Chain for $1.4B and a $4.15B debt tender offer, enhancing financial flexibility.
The outlook is mixed: cost-cutting initiatives and strategic divestitures provide upside, but competitive pressures from Amazon and soft shipping demand pose risks. With 57% of analysts rating it Buy and a $360.27 price target, the stock offers potential appreciation if margin recovery aligns with guidance, though execution remains key.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a P/B ratio of 8.35 and negative profitability metrics. The stock is technically bullish based on moving averages, though oscillators are neutral. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, announced on June 9, 2026 (Reuters). Earnings have been mixed, with two misses and one beat in the last three quarters.
The acquisition by GSK provides a near-term price floor but limits upside. Risks include ongoing financial losses and shareholder litigation questioning deal fairness. Analyst sentiment is mixed with 42% buy ratings. The stock's outlook hinges on deal completion, with fundamental challenges persisting until closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
